Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-02-15

Study Completion Date

2023-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In January 2020, researchers isolated and sequenced in China from patients with severe atypical pneumonia a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has rapidly spread throughout the world. SARS-CoV-2 may trigger hyperstimulation of immune system with an autoinflammatory response but also the development of an autoimmune process. These autoimmune responses may also develop through the molecular mimicry between virus and human-self components. Multiple autoantibodies have been described in COVID-19 patients.

Annexin A2 (ANXA2), an endothelial cell receptor for plasminogen and tissue plasminogen activator has been identified as a new autoantigen in antiphospholipid syndrome. ANXA2 has been identified as candidate autoantigen recognized by SARS patient sera. ANXA2 contributes also to pulmonary microvascular integrity. These data lead to identify anti-ANXA2 antibodies in COVID-19 patient sera and to know if the presence of these antibodies is associated with pulmonary injury or thrombosis in COVID-19 and represents a marker of severity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?

NCT04469634

SARS-CoV2 COVID-19

COMPLETED NA

Antibodies Responses to COVID-19 Infection in Hospitalized Patients

NCT04520880

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV 2 Infection) Hospitalized Patients Laboratory-confirmed SARS-CoV 2 Infection

UNKNOWN

Antibodies and Immunity After Vaccination of Recovered Patients With COVID-19 and Long COVID-19 Symptoms

NCT05484700

Long COVID-19

UNKNOWN

Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19

NCT04543006

Covid19

UNKNOWN NA

Investigating Development of Autoimmunity in Post-Acute COVID-19 Syndrome (PACS)

NCT05459506

COVID-19 Pandemic

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years and older
* All patients hospitalized in Amiens University Hospital with COVID-19 infection

Exclusion Criteria

* Autoimmune diseases
* Chronic viral infection by hepatitis B virus, hepatitis C virus or human immunodeficiency virus (HIV)
* Immunosuppressive treatment
* Solid tumors
* Hematological malignancies

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No